Pituitary surgery had to be postponed due to the severe heart failure.
Optimal pharmacological treatment of systolic heart failure was administered (beta-blocker, ACE inhibitor, diuretics including anti-aldosterone agent) and, as described in such severe conditions,6,7 2 adrenolytic drugs (metyrapone and ketoconazole) were initiated: UFC was normalized within 2 months (Table 1).
Unfortunately, a new episode of acute heart failure occurred two months after initial presentation. Transthoracic cardiac echography showed mitral insufficiency related to rupture of the mitral valve pillar. Percutaneous transluminal angioplasty and stenting (bare metal) was performed in the obtuse marginal artery. Another cardiac MRI then revealed an impaired lateral contractility (territory of the marginal branch) related this time to necrosis (Fig. 3). Infective endocarditis was ruled out (hemocultures were negative and no vegetation was visualized at transesophageal echocardiography).
In spite of optimal treatment and normalization of cortisol levels, no improvement was found in the LVEF 6 months after discovery of the Cushing's disease (Table 1).
Thus a single-chamber defibrillator was implanted for primary prevention, and percutaneous mitral valve repair (Mitraclip) was performed to treat the mitral regurgitation.
After 1 year, since LVEF remained at 30%, cardiac transplantation was discussed.
In view of the patient's heart failure, anesthesia for transphenoidal surgery was considered too dangerous; therefore, stereotaxic radiotherapy was performed to treat the CD 14 months after initial presentation. While awaiting the therapeutic effects of the pituitary irradiation, tolerance and efficacy of the 2 adrenolytic agents proved acceptable.
Cardiovascular complications, including myocardial ischemia, left ventricular hypertrophy and cardiomegaly account in part for the higher mortality rate among patients with Cushing's syndrome.8 Some studies having examined the relationship between cardiac dysfunction and hypercortisolism, found that cardiac remodeling is independent of hypertension, and is probably due to a direct action of cortisol on myocardial tissue via glucocorticoid receptors.2–4
A recent cardiac MRI study showed that patients with Cushing's syndrome have lower left ventricular, right ventricular, and left atrial ejection fractions and increased left ventricular mass.5 Repetition of imaging after treatment revealed that these systolic dysfunctions and structural changes are reversible upon correction of hypercortisolism. None of the patients in this study had DCM.
Several cases with DCM related to hypercortisolism have been published9–18 (Table 2).
Interestingly, all these cases showed an improvement in LVEF after several months of cortisol normalization (median LVEF improvement of 30% [min: 15%; max: 42%]; in a median time of 9 months [min: 4; max: 18]). Cushing's syndrome was due to unilateral adrenal adenoma in 5 cases,11,12,14,15,17 ACTH-secreting adenoma in 4 cases,9,10,13,18 and of unknown cause in 1 case.16 LVEF improvement was noted whatever the initial etiology, with a median improvement of 30% (min: 15%; max: 42%) for adrenal adenomas, 25% (min: 15%; max: 33%) for pituitary adenomas, and 38% after bilateral adrenectomy in the subject for whom the cause was undetermined. In view of these observations, DCM related to hypercortisolism could be considered as “reversible.”
Here we have reported the first case showing no improvement of DCM in a context of Cushing's syndrome. At presentation the cardiomyopathy could only be attributed to hypercortisolism (usual other causes of DCM were eliminated, MRI initially showed no ischemic signs; however, unfortunately, several weeks later the patient suffered an acute coronary syndrome with rupture of the mitral pillar and objective signs of necrosis in the lateral territory (MRI). This combination of different causes of DCM (hypercortisolism, ischemia, and valvular defect) could explain the absence of improvement of LVEF in response to a eucortisolemic state.
Another possible explanation can be a publication bias due to the selective reporting of cases in which DCM had been reversed.
The standard treatment of CD is transphenoidal surgery with up to 65% remission rate for macroadenomas.19 For recurrent or residual disease, therapeutic possibilities are second transphenoidal surgery, radiotherapy, medical adrenolytic therapy (mainly comprising mitotane, metyrapone, and ketoconazole, and more rarely etomidate and mifepristone) or bilateral adrenalectomy in cases of uncontrolled cortisol levels.
Unfortunately for our patient, anesthesia for pituitary surgery was contraindicated due to very low LVEF. Combination of 2 adrenolytic agents (metyrapone, blocking the 11-beta-hydroxylase enzyme; and ketoconazole, blocking several steps in cortisol synthesis) normalized cortisol levels and tolerance was good. The observed efficacy is consistent with results from 2 studies in which this combination provided rapid control of severe hypercortisolism elicited by ACTH-dependent Cushing's syndrome6 (a combination of mitotane, metyrapone, and ketoconazole in this study) and by ectopic ACTH syndrome or adrenal carcinoma.7
Our patient was treated by external pituitary radiation, the therapeutic effects of which will be delayed.
In conclusion, we report here the case of a DCM as a presenting feature of CD, without improvement of LVEF after normalization of cortisol level (probably explained by subsequent associated ischemic lesions).
We would like to thank Pr Didier Revel for his interpretation of the cardiac MRI, and Dr Thibault Perret for his kind advices.
1. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab
2. Fallo F, Budano S, Sonino N, et al. Left ventricular structural characteristics in Cushing's syndrome. J Hum Hypertens
3. Muiesan ML, Lupia M, Salvetti M, et al. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol
4. Yiu KH, Marsan NA, Delgado V, et al. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. Eur J Endocrinol
5. Kamenický P, Redheuil A, Roux C, et al. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab
6. Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab
7. Corcuff J-B, Young J, Masquefa-Giraud P, et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol
8. Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab
9. Hersbach FM, Bravenboer B, Koolen JJ. Hearty hormones. Lancet
10. Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab
11. Marazuela M, Aguilar-Torres R, Benedicto A, et al. Dilated cardiomyopathy as a presenting feature of Cushing's syndrome. Int J Cardiol
12. Petramala L, Battisti P, Lauri G, et al. Cushing's syndrome patient who exhibited congestive heart failure. J Endocrinol Invest
13. Ma RCW, So WY, Tong PCY, et al. Adiposity of the heart revisited: reversal of dilated cardiomyopathy in a patient with Cushing's syndrome. Int J Cardiol
14. Yong TY, Li JYZ. Reversible dilated cardiomyopathy in a patient with Cushing's syndrome. Congest Heart Fail Greenwich Conn
15. Banna R Al, Husain A, Aali F Al, et al. Reversible Cushing dilated cardiomyopathy mimicking peripartum cardiomyopathy with successful subsequent pregnancy. BMJ Case Rep
2011; pii: bcr0920114825. doi: 10.1136/bcr.09.2011.4825.
16. Johnston PC, Atkinson AB, Moore MJ, et al. An unusual cause of reversible cardiomyopathy. Ulster Med J
17. Shibusawa N, Yamada M, Hashida T, et al. Dilated cardiomyopathy as a presenting feature of Cushing's syndrome. Intern Med Tokyo Jpn
18. Kim JH, Kim SY, Park JH. Dilated cardiomyopathy with left ventricular thrombi as a presenting feature of Cushing disease. Can J Cardiol
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
19. Aghi MK. Management of recurrent and refractory Cushing disease. Nat Rev Endocrinol